Key result
Long-term low-dose aspirin use in patients with cardio-cerebra-vascular ischemic diseases was associated with a decreased risk of pneumonia compared to non-use (aHR 0.890).
Why the study?
To evaluate the association between long-term low-dose aspirin use and the risk of pneumonia in patients with cardio-cerebra-vascular ischemic diseases.
Does long-term low-dose aspirin use reduce the risk of pneumonia in patients with cardio-cerebra-vascular ischemic diseases?
Cohort (n=31,568)
Does long-term low-dose aspirin use reduce the risk of pneumonia in patients with cardio-cerebra-vascular ischemic diseases?
Hazard Ratio: 0.89 (95% CI 0.837–0.945)
Absolute Event Rate: 3.6% vs 3.95%
p-value: p=0.0002
Long-term low-dose aspirin use in patients with cardio-cerebra-vascular ischemic diseases is associated with a significantly decreased risk of developing pneumonia.
Hypothesis-generating for pneumonia risk reduction with aspirin; should not change practice pending randomized confirmation.
This study evaluated the association between long-term low-dose aspirin use and decreased risk of pneumonia in patients with cardio-cerebra-vascular ischemic diseases (CCVDs). This retrospective cohort study used records from Taiwan's National Health Insurance Research Database of claims made between 1997 and 2013. After propensity score matching (PSM), patients who took a low dose of aspirin for more than 90 days within 1 year of diagnosis with CCVDs were identified as the exposure group (n = 15,784). A matched total of 15,784 individuals without aspirin use were selected for the non-aspirin group. The main outcome was the development of pneumonia after the index date. Multivariable Cox regression analysis and Kaplan–Meier survival analysis were performed to estimate the adjusted hazard ratio (aHR) and cumulative probability of pneumonia. The result after PSM indicated a lower hazard ratio for pneumonia in aspirin users (aHR = 0.890, 95% confidence interval = 0.837–0.945). Therefore, patients with CCVDs who took aspirin had a lower risk of developing pneumonia than those who did not. In conclusion, this population-based cohort study demonstrated that long-term low-dose aspirin use is associated with a slightly decreased risk of pneumonia in patients with CCVDs.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2021) conducted a cohort in Cardio-cerebra-vascular ischemic diseases (CCVDs) (n=31,568). Low-dose aspirin vs. Non-aspirin use was evaluated on Development of pneumonia (aHR 0.890, 95% CI 0.837-0.945, p=0.0002). Long-term low-dose aspirin use in patients with cardio-cerebra-vascular ischemic diseases was associated with a decreased risk of pneumonia compared to non-use (aHR 0.890).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: